Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BI 765423

Next Previous
Drug Profile

BI 765423

Alternative Names: BI-765423

Latest Information Update: 01 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Class Antibodies; Antifibrotics
  • Mechanism of Action Interleukin 11 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Fibrosis

Most Recent Events

  • 25 Jun 2025 Boehringer Ingelheim plans a phase II trial for Idiopathic Pulmonary Fibrosis in the USA, Australia, Belgium, Canada, Germany, Italy, Japan, South Korea and Spain (IV) (NCT07036523)
  • 30 Jan 2024 Boehringer Ingelheim plans to initiate phase I trial (In volunteers) (IV) in February 2024 (NCT06232252)
  • 09 May 2023 Phase-I clinical trials in Fibrosis (In volunteers) in Belgium (IV) (NCT05658107)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top